Connect with us

Cannabis

CBDCapitalGroup Releases Pilot Results on Medical Outcome Study That Measured CBD Efficacy and is Expanding Participation to Portfolio Company Mana Botanics

GlobeNewswire

Published

on

SAN DIEGO, CA, Feb. 11, 2020 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — CBDCapitalGroup (“CCG” or the “Company”), a CBD nutraceuticals investment and scaling company, today announced that it has released preliminary results for the first-ever program to measure cannabidiol (CBD) efficacy using the qualitative Short Form (SF)-36 Health Survey. Additionally, the Company is expanding SF-36 Survey participation to its portfolio company, Mana Artisan Botanics™ (“Mana Botanics”).
CBDCapitalGroup CEO David Metzler said, “We used this universally established healthcare Medical Outcome Study to measure if products actually work, and do they really improve the Quality of Life of consumers. The pilot data is potentially a game-changer for the whole industry once confirmed because it suggests that consumers taking CBD for more than three months (13+ weeks) have higher Quality of Lives scores. This indicates that hemp and CBD products appear to improve Quality of Life (QoL Scores) for the conditions they are using it for pain, anxiety, and insomnia as measured by the SF-36. More research will be done across additional companies, and we will publish additional data in the coming months. For now, we are optimistic that we have a unique methodology to measure CBD impact on consumers’ Quality of Life.”  CCG’s goal is to see this SF-36 survey used universally by CBD companies to prove that their products are actually improving the Quality of Lives of consumers and potentially even help to create a federal policy on quality and standards. In September 2019, CCG announced that its portfolio company, Medix CBD, would be the first CBD company ever to participate in the SF-36 Survey. In the coming weeks, the Company will be expanding participation to Mana Botanics, an additional CCG portfolio company.Participants were required to complete the SF-36 Survey twice, with the second survey taking place four weeks after the first. Preliminary data shows that Medix CBD SF-36 Survey participants reported an increase of 5.42% in overall Quality of Life scores after taking Medix CBD products for at least four weeks. The study was administered by Steve Myers, the former Chief Technology Officer of Optum, a UnitedHealth Group company, who said about the study, “The data indicates that CBD usage appears to offer individuals a latent therapeutic effect as measured by the SF-36 across all sub-domains.”Data also reveals that most participants reported “anxiety” as their condition for taking CBD (59.61%), followed by “chronic pain” (50.81%), “insomnia” (42.67%), “acute pain” (22.80%), and “other” (17.59%). Additionally, the most common age ranges for those taking CBD are 55 to 64, and the majority of people taking it are female (60.5%) compared to male (39.5%). Most individuals reported use of CBD as needed (55.29%) and the rest reported use of CBD daily (44.71%). The SF Medical Outcome Study (“MOS”) was originally designed by the U.S. Government and the Rand Research Corporation to calculate the cost-effectiveness of health treatments. Since established, the survey has been given to millions of people to demonstrate statistical-actuarially validated outcomes. CCG and its portfolio companies are dedicated to research that provides the cannabis industry with the information needed to continue to rapidly grow into a well-respected industry. Zak Garcia, interim CEO of Mana Botanics, said, “Mana looks forward to working alongside CCG with a united goal of bringing more research on CBD’s potential effects to consumers while proving the efficacy of our own artisan products.”About CBDCapitalGroup: CBDCapitalGroup (“CCG” or the “Company”) is an investment and scaling company that acquires and develops mid-stage CBD and hemp nutraceutical companies to promote both financial and professional success. The Company is led by a group of seasoned entrepreneurs who have managed over $1 billion in combined revenue over their careers, and now apply their diverse business experiences to establish trust, quality standards and efficiencies in the CBD market. The Company provides CBD industry entrepreneurs a faster path to revenue growth and liquidity with capital, expert advice and operational resources needed to scale already profitable businesses.About Medix CBD: Medix CBD is a premier producer and distributor of cannabidiol (CBD) products throughout the United States. The company’s hemp is expertly sourced in Kentucky and every ingredient and product is lab-tested to ensure the highest quality for consumers everywhere. From tinctures and topicals to vapes, pet products and gummies, Medix CBD provides products for a variety of consumer tastes and preferences.About Mana Artisan Botanics™:Mana Artisan Botanics™, Hawaii’s first wellness-driven hemp company, handcrafts phytocannabinoid-rich products for endocannabinoid system (ECS) support. Based on the Big Island of Hawaii, the company offers artisanal, whole-plant hemp extracts, infused with pure Hawaiian botanicals. The Mana team members all share a deep desire for wholesome, healthful living, and their efforts demonstrate a commitment to regenerative agriculture, the local economy, and holistic health education. Mana Artisan Botanics™ products are Good for Body & Soil™. For more information visit manabotanics.com and connect with us on Facebook, Instagram and Twitter.FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE:These statements have not been evaluated by the FDA and are not intended to diagnose, treat or cure any diseaseLEGAL DISCLOSURE:None of the parties involved, including CBDCapitalGroup and Medix CBD, sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA). Medix CBD does grow, sell, and distribute hemp-based products and are involved with the federally legal distribution of medical marijuana-based products within certain international markets. Cannabidiol is a natural constituent of hemp oil.PUBLIC RELATIONS CONTACT: Kathryn ReinhardtAccount Manager, CMW MediaP: 858-283-4005kathryn@cmwmedia.comwww.cmwmedia.com

Cannabis

Canada’s Legal Cannabis Industry Advocates for Equitable Financial Treatment

Newsfile

Published

on

Toronto, Ontario–(Newsfile Corp. – March 27, 2020) – The regulated cannabis industry has recently united to address a critical issue it has faced since its inception: a lack of equitable access to banking services and financial support. The fallout from the COVID-19 pandemic has highlighted the need to fix this while demonstrating that cannabis is an essential product.

We commend the individuals and organizations that have been vocal in their support for the cause: Don Davies (MP), Nathaniel Erskine-Smith (MP), Scott Reid (MP), Dan Sutton (Tantalus Labs), The Canadian Chamber of Commerce, and the Cannabis Council of Canada. Their lobby efforts have been directed towards the Business Development Bank of Canada (BDC), Bill Morneau P.C., M.P. (Minister of Finance), and Navdeep Bains P.C., M.P. (Minister of Innovation, Science and Industry), in an attempt to influence federal decision makers.

In solidarity, Alan Aldous has created an educational website to highlight the positive contributions to the Canadian economy, www.LegalTender.ca. We have also organized a coalition of industry experts, associations, and companies to advocate for change, including the Cannabis Council of Canada, NORML Canada, the British Columbia Independent Cannabis Association, the Ontario Independent Cannabis Association, the Alberta Cannabis Micro Licence Association, and The Cannabis Conservatory.

“The cannabis industry is doing its best to provide Canadians with an uninterrupted supply of legal cannabis, but it is not immune to the effects of COVID-19. Cannabis businesses deserve access to the same financial support being made available to other industries. Cannabis sector jobs are just as worthy of protection as any other,” says Trina Fraser, a prominent cannabis industry lawyer at firm Brazeau Seller Law.

In just one day, hundreds of Canadians have signed this urgent petition (https://bit.ly/2QKvwTQ) advocating for equitable treatment by the Business Development Bank of Canada (BDC) and Federal Government of Canada. We are thrilled by the response so far, and encourage hard-working Canadians to sign, share, and have their voices heard.

About Alan Aldous

Alan Aldous is a public relations agency for the emerging cannabis and psychedelics markets led by leading Canadian cannabis media professionals. The agency works with all the major newswire distribution services across North America, which makes transitioning to Alan Aldous easy for companies with existing PR efforts.

For media contact Alex Krause, Head Publicist, 519-835-8345, alex@alanaldous.com.

Cannot view this image? Visit: https://i1.wp.com/grassnews.net/wp-content/uploads/2020/03/canadas-legal-cannabis-industry-advocates-for-equitable-financial-treatment.png?w=740&ssl=1

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/53883

Continue Reading

Cannabis

REPEAT – AgraFlora Organics’ GTA Facility Receives Amendments Necessary to Launch CBD Business

GlobeNewswire

Published

on

VANCOUVER, British Columbia, March 27, 2020 (GLOBE NEWSWIRE) — AgraFlora Organics International Inc.  (“AgraFlora” or the “Company”) (CSE: AGRA) (Frankfurt: PU31) (OTCPK: AGFAF) is pleased to announce its wholly owned subsidiary Sustainable Growth Strategic Capital Corp. (“SGSC”), a federally licensed cannabis company based in the Greater Toronto Area (GTA), has received Health Canada approval to commence extraction at its licensed facility pursuant to an amendment to its Standard Processing License.  SGSC also holds Standard Cultivation and Medical Sales Licenses issued pursuant to the Cannabis Act.
SGSC has been actively engaged in the Canadian CBD business, working with partner farmers to optimize the harvest to hemp-crops to maximize the efficiency of subsequent CBD extraction.  In March, SGSC commenced a trial extraction (the “Trial”) of hemp-biomass which will be extracted using third-party extraction services and sold as a combination of CBD Crude Oil, CBD Distillate and CBD Isolate to Canadian purchasers.  If the Trial yields favourable results with respect to product quality, efficiency and margin SGSC intends to move quickly with a second production cycle of up to 1,300 KG of high-quality hemp biomass containing CBD concentrations over 8%.The current SGSC facility is designed to facility up to 250,000 kg of biomass extraction capacity utilizing chilled ethanol for primary extraction followed by distillation and/or isolation.   SGSC intends to use the Trial and subsequent third party extraction cycles to properly design and size its in-house extraction capacity to maximize the profitability and return on capital invested.   Once built, SGSC intends to improve its profitability by reducing the cost of extraction, purification and fulfilment by bringing those processes in-house. About AgraFlora Organics International Inc.AgraFlora Organics International Inc. is a growth oriented and diversified company focused on the international cannabis industry. It owns an indoor cultivation operation in London, ON and is a joint venture partner in Propagation Services Canada Inc. and its large-scale 2,200,000 sq. ft. greenhouse complex in Delta, BC. The Company is also retrofitting a 51,500-square-foot good manufacturing practice (“GMP”) edibles manufacturing facility in Winnipeg, Manitoba. AgraFlora has a successful record of creating shareholder value and is actively pursuing other opportunities within the cannabis industry. For more information please visit: www.agraflora.com.ON BEHALF OF THE BOARD OF DIRECTORSBrandon Boddy
Chairman & CEO
T: (604) 398-3147 
The CSE and Information Service Provider have not reviewed and does not accept responsibility for the accuracy or adequacy of this release.Forward-looking Information Cautionary StatementExcept for statements of historic fact, this news release contains certain “forward-looking information” within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as “plan”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate” and other similar words, or statements that certain events or conditions “may” or “will” occur. Forward-looking statements are based on the opinions and estimates at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking statements including, but not limited to delays or uncertainties with regulatory approvals, including that of the CSE. There are uncertainties inherent in forward-looking information, including factors beyond the Company’s control. There are no assurances that the business plans for AgraFlora Organics described in this news release will come into effect on the terms or time frame described herein. The Company undertakes no obligation to update forward-looking information if circumstances or management’s estimates or opinions should change except as required by law. The reader is cautioned not to place undue reliance on forward-looking statements. Additional information identifying risks and uncertainties that could affect financial results is contained in the Company’s filings with Canadian securities regulators, which are available at www.sedar.com.

Continue Reading

Cannabis

Israel Begins Cannabis Exports to Meet Unmet Medical Needs — CFN Media

Newsfile

Published

on

Seattle, Washington–(Newsfile Corp. – March 27, 2020) – CFN Media (OTCQB: CNFN), the leading agency and financial media network dedicated to the legalized North American cannabis industry announces publication of an article discussing how Israel has shipped the first cannabis export to the UK, marking a new era in Israeli cannabis.

Israel has long been an international center for cannabis research. THC, the psychoactive ingredient in cannabis, and CBD, the plant’s predominant non-psychoactive ingredient, were first isolated and defined by Israeli researcher Dr. Raphael Mechoulam in the early 1960s. Research continued there in the following decades, and the Israeli government has contributed greatly to the country’s prominence in the global cannabis industry.

In Israel, medical cannabis is legal while recreational use remains technically illegal, though the government decriminalized recreational use to some extent in 2017. Government agencies provide funding for cannabis research. In January 2019, the government passed a law to allow exports of medical cannabis, though the first export was announced a year later in January 2020. With that recent development, the table appears set for growth in the Israeli cannabis market.

Click below to view more on Isracann Biosciences – Israel’s First Pure Play Cannabis Firm

Cannot view this video? Visit:
https://www.youtube.com/watch?v=Txysv2Sd9SM

Unmet Need in Europe

BOL Pharma is the Israeli company that announced the first export from the country, with a shipment destined for centers that specialize in the treatment of children with epilepsy and autism in the United Kingdom. The company’s CEO, Dr. Tamir Gedo, stated, “This is truly welcome news and a real breakthrough for the Israeli medical cannabis market. The Israeli cannabis industry has a huge competitive edge in the global arena, compared to many countries trying to enter the cannabis sector… Further opening of the market to exports will enable Israel to become a world leader in the coming years.”

Click Here To Receive Isracann’s Investor Presentation

The UK legalized medical cannabis in late 2018. Since then, patients have had a hard time getting prescribed treatments in a timely fashion, with most of the supply coming from foreign countries but facing restrictive regulations. As a result, in early March 2020, the UK government announced a change in import restrictions designed to increase the flow of timely medicinal products to registered patients.

This dynamic is common throughout Europe, with countries adopting medical programs without the infrastructure, both regulatory and physical, to provide supply to its own patients. Israel, with its strategic location combined with governmental commitment to the industry, is in prime position to pick up some of the slack.

Isracann Biosciences Poised to Move

Isracann Biosciences Inc. (CSE: IPOT) (OTC: ISCNF) is an Israeli-based cannabis company poised to enter both the Israeli domestic and the European export cannabis markets. The company is advancing its fully-funded 230,000 sq ft hybrid greenhouse cultivation project while also advancing a partnership with a late stage project consisting of approximately 200,000 sq ft of greenhouses located on over 880,000 sq ft of agricultural land. In conjunction with the cultivation projects, Isracann is developing European distribution channels while ensuring that all aspects of its business, from cultivation through processing and manufacturing, comply with European Union GMP regulations necessary for international trade.

While laying the groundwork for an extensive European export operation, the company is certainly not foregoing the burgeoning domestic opportunity in Israel. The country, as of late 2019, had about 46,000 registered patients. Isracann expects this number to roughly double by the end of 2020, by which time the company hopes to be harvesting and distributing products.

The company recently announced a joint venture agreement with two near-term farm operations in the Sharon Plain region of Israel. The IMC-compliant farms operate under preliminary cannabis nursery and cultivation licenses and are preparing to commence planting within weeks with 160,000 sq. ft. of greenhouse canopy on two million sq. ft. of private land. The move paves the way for the company to ramp up sales faster than it expected and could help drive near- and long-term shareholder value.

In a recent two-part interview with CFN Media, Isracann Biosciences CEO Darryl Jones outlined the company’s strategy, assets, and partnerships. He talked about some of the advantages inherent in the Israeli market (ideal climate for cultivation, regulatory environment, advanced research, widespread domestic use, proximity to Europe, etc.).

Click Here To Receive Isracann’s Investor Presentation

CEO Video Interview #1

Click Below to View Video Interview #1: Isracann Biosciences CEO Darryl Jones 

Cannot view this video? Visit:
https://www.youtube.com/watch?v=XXhtd4lYAlk&t=28s

Click Below to View Video Interview Part #2: Isracann Biosciences CEO Darryl Jones

Cannot view this video? Visit:
https://www.youtube.com/watch?v=PddKzFeZGr4&t=18s

Looking Ahead

The very first medical cannabis shipment from Israel to the UK marks a new era in the promising Israeli cannabis industry. With the country’s government backing research and development efforts, as well as implementing rules to encourage growth of the industry both domestically and internationally, Israel has cemented its place as a leader for the global cannabis market. The year ahead promises to be pivotal for both the industry in general, and for Isracann Biosciences in particular as the company executes its vision of a comprehensive farm-to-consumer cannabis company. Keep an eye out as the plan unfolds.

Click Here To Receive Isracann’s Investor Presentation

Click here to read the full article: https://bit.ly/2QNGwA1

Click Here to Receive CFN Media’s Newsletter Every Week in Your Inbox

Isracann Biosciences
CEO
Darryl Jones
Djones@isracann.com
855-205-0226

CFN Enterprises
President
Frank Lane
206-369-7050
Flane@cannabisfn.com

About CFN Media

CFN Enterprises Inc. (OTCQB: CNFN) is the owner and operator of CFN Media, the leading agency and digital financial media network dedicated to the legal cannabis industry.

For Visitors and Viewers

CFN Media’s Cannabis Financial Network (CannabisFN.com) is the destination for savvy investors and business people profiting from the worldwide cannabis industry. Viewers will see breaking news, exclusive content and original programming involving the people, companies and investments shaping the industry.

For Cannabis Businesses & Companies

CFN Media is a leading agency and financial media network dedicated to the cannabis industry. We help private, pre-public and public cannabis companies in the US and Canada attract capital, investors and media attention.

Our powerful digital media and distribution platform conveys a company’s message and value proposition directly to accredited and retail investors and national media active in the North American cannabis markets.

Since 2013, CFN Media has enabled the world’s preeminent cannabis companies to thrive in the capital and public markets.

Learn how to become a CFN Media client company, brand or entrepreneur: https://www.cannabisfn.com/become-featured-company/

Disclaimer

The above article is sponsored content. CannabisFN.com and CFN Media, have been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/53879

Continue Reading

Trending Online

Grassnews is part of PICANTE Media and Events, a leading media and boutique event organizer in the European Union with a monthly reach of +50,000 readers. The official company (PROSHIRT SRL), has been listed for 4 years in a row among the top 3 Advertising and market research agencies in the local Top Business Romania Microcompanies based on the Financial Reports. Grassnews digests / hand picks the latest news about the CBD / Legal Cannabis industry and serves them to you daily.

Contact us: sales@picante.today

Editorial / PR Submissions

© Grassnews .com 2019 - 2020 - part of PICANTE Media. All rights reserved. Registered in Romania under Proshirt SRL, Company number: 2134306, EU VAT ID: RO21343605. Office address: Blvd. 1 Decembrie 1918 nr.5, Targu Mures, Romania